Home/Filings/4/0001415889-24-004790
4//SEC Filing

Venrock Healthcare Capital Partners III, L.P. 4

Accession 0001415889-24-004790

CIK 0001348911other

Filed

Feb 21, 7:00 PM ET

Accepted

Feb 22, 4:15 PM ET

Size

17.6 KB

Accession

0001415889-24-004790

Insider Transaction Report

Form 4
Period: 2024-02-20
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Koh Bong Y
10% Owner
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Shah Nimish P
10% Owner
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Transactions
  • Purchase

    Pre-Funded Warrants (Right to Buy)

    2024-02-20$15.25/sh+655,738$9,999,349655,738 total(indirect: By Funds)
    Exercise: $0.00Common Stock (655,738 underlying)
Footnotes (3)
  • [F1]Consists of (i) 172,394 securities held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 17,246 securities held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 466,098 securities held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
  • [F2]The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
  • [F3]VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

Issuer

KalVista Pharmaceuticals, Inc.

CIK 0001348911

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001738048

Filing Metadata

Form type
4
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 4:15 PM ET
Size
17.6 KB